Congress mandates pediatric cancer drug testing, extends pharma tax incentive

What it does

This bill amends federal drug-approval law to require pharmaceutical companies developing molecularly targeted cancer drugs to conduct pediatric studies as a condition of adult approval, and extends a tax-incentive program (priority review vouchers) that rewards companies for developing rare pediatric disease treatments through 2029. The bill aims to ensure children with cancer have access to targeted therapies and to incentivize development of drugs for rare pediatric diseases.

Why we flagged it

The bill's core mechanism is a regulatory requirement that pharmaceutical companies conduct pediatric cancer studies as a condition of adult drug approval, paired with an extension of a tax-incentive voucher program for rare pediatric disease drugs. Both mechanisms are designed to increase drug development and testing in pediatric populations.

What the text implies

• The pediatric study requirement applies only to 'molecularly targeted' cancer drugs with novel active ingredients or combinations, potentially excluding older chemotherapy regimens from pediatric testing mandates.
• Priority review vouchers are transferable assets that can be sold to other companies, creating a secondary market where large pharma may purchase expedited review rights from smaller developers, concentrating the benefit.
• The 3-year implementation delay before pediatric study requirements take effect may allow companies to rush applications through before the rule applies, reducing the bill's practical impact.
• GAO study (due year 10) will assess voucher program effectiveness, but by then the program will have operated for 5 years post-extension with no interim accountability mechanism.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Children with cancer and rare pediatric diseases gain access to molecularly targeted therapies and incentivized drug development that would otherwise not occur. The pediatric study requirement ensures drugs are tested in children before approval, improving safety and efficacy data for pediatric populations. The priority review voucher extension maintains a proven incentive for rare pediatric disease drug development.

Who stands to gain

• pharmaceutical companies developing molecularly targeted cancer drugs
• biopharmaceutical firms developing rare pediatric disease treatments
• companies purchasing priority review vouchers on secondary market

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), GAO (Government Accountability Office), Section 505 (Federal Food, Drug, and Cosmetic Act), Section 505B (pediatric study plan requirements), Section 529 (priority review voucher program), Section 351 (Public Health Service Act), Committee on Energy and Commerce, Committee on Health, Education, Labor, and Pensions

Where it stands

20 cosponsors: 10 Democrats, 10 Republicans.

• Mar 11, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 11, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

34 lobbying clients named this bill on 48 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $16,662,605 in lobbying spend. A filing names 6 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 98% of bills with at least one filing.

Markwayne Mullin, the sponsor, reported $979,756 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $8,410,000 on 1 filing
• Novartis — $1,410,000 on 1 filing
• National Association of Children's Hospitals (n.a.c.h.) — $1,370,000 on 1 filing
• Acadia Pharmaceuticals — $1,290,000 on 2 filings
• Astrazeneca Pharmaceuticals Lp — $670,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.